|1.||Tedeschini, Enrico: 1 article (04/2011)|
|2.||Papakostas, George I: 1 article (04/2011)|
|3.||Levkovitz, Yeciel: 1 article (04/2011)|
|4.||Ungvari, Gabor S: 1 article (12/2010)|
|5.||Ling, Walter: 1 article (01/2009)|
|6.||Shoptaw, Steven J: 1 article (01/2009)|
|7.||Heinzerling, Keith: 1 article (01/2009)|
|8.||Kao, Uyen: 1 article (01/2009)|
|9.||Guedes, Antonio Carlos Martins: 1 article (01/2009)|
|10.||Carvalho, Maria de Lourdes Ribeiro de: 1 article (01/2009)|
|1.||Depressive Disorder (Melancholia)
01/01/1979 - "Both drugs appeared to be equally effective overall in patients with endogenous depression, although when amineptine was given as the second treatment there was an improvement in retardation. "
07/01/1997 - "Efficacy of amineptine in the prevention of relapse in unipolar depression."
07/01/1997 - "The clinical properties of amineptine, a mainly dopaminergic antidepressant, were assessed in a double-blind controlled study involving patients fulfilling Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for unipolar depression. "
01/01/1989 - "Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with amineptine (200 mg/day) for 40 days (mean). "
01/01/1985 - "Amineptine in the management of the depressive syndromes."
|2.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
01/01/2009 - "Two studies found that amineptine significantly reduced discontinuation rates and improved overall clinical presentation, but did not reduce withdrawal symptoms or craving compared to placebo. "
01/01/2009 - "Amineptine showed reduction in discontinuation rates and improvement in clinical presentation compared to placebo, but had no effect on reducing withdrawal symptoms or craving. "
01/01/2001 - "Amineptine has limited benefits on some amphetamine withdrawal symptoms. "
01/01/2001 - "However, no direct benefit of amineptine on amphetamine withdrawal symptoms or craving was shown. "
01/01/1989 - "Particularly in reactive and neurotic depression (nonpsychotic depression according to INSERM) and dysthymic disorders according to DSM-III, amineptine induced an improvement in 90% of patients. "
04/01/2011 - "We defined antidepressants as those with a letter of approval by the US, Canadian, or European Union drug regulatory agencies for treatment of MDD or dysthymic disorder, which included the following: amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, trimipramine, protriptyline, dothiepin, doxepin, lofepramine, amoxapine, maprotiline, amineptine, nomifensine, bupropion, phenelzine, tranylcypromine, isocarboxazid, moclobemide, brofaromine, fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, zimelidine, tianeptine, ritanserin, trazodone, nefazodone, agomelatine, venlafaxine, desvenlafaxine, duloxetine, milnacipran, reboxetine, mirtazapine, and mianserin. "
|4.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
01/01/1989 - "The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome."
01/01/1989 - "Forty patients who satisfied the criteria for irritable bowel syndrome and had a Hamilton 24-item score above 15 were randomly assigned to receive either amineptine 200 mg/day or placebo in a double-blind clinical trial. "
|3.||Dopamine Agonists (Dopamine Agonist)